Enterprise Value
-10.46M
Cash
16.9M
Avg Qtr Burn
-2.933M
Short % of Float
27.38%
Insider Ownership
0.10%
Institutional Own.
1.09%
Qtr Updated
12/31/23
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
APVO436 (anti-CD123 x anti-CD3) +/- Venetoclax + Azacitidine Details Myelodysplastic syndrome, Acute myeloid leukemia, Cancer | Phase 1/2 Initiation | |
ALG.APV-527 (4-1BB x 5T4) Details Cancer, Solid tumor/s, Breast cancer, Colorectal cancer , Non-small cell lung carcinoma, Pancreatic cancer | Phase 1 Data readout |